

[Cefalexin](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics](#)

ATC codes: [J01DB01](#)

Indication

Chronic obstructive pulmonary disease with acute exacerbation ICD11 code: [CA22.0](#)

INN

Cefalexin

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Formulations

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid ; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate) ; 500 mg (as monohydrate)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Cefalexin](#)

DrugBank

[Cefalexin \(Cephalexin\)](#)

Expert Committee recommendation

The Expert Committee recommended inclusion of a new, higher strength formulation of cefalexin solid oral dosage form on the core list of the EML for the treatment of exacerbations of chronic obstructive pulmonary disease. The Committee noted that the proposed strength formulation is higher than those currently included on the Model List, and is appropriate and aligned to meet recommended doses for treatment of adults, with the advantages of a reduced pill burden.

Summary of evidence

Most adult patients diagnosed with exacerbations of COPD can be successfully treated with cephalexin 500 mg every 12 hours for 5 days. The higher strength formulation will allow for a reduced pill burden to complete a course of treatment compared to the currently listed 250 mg strength formulation, and should facilitate adherence to treatment.

EML recommendations: Chronic obstructive pulmonary disease with acute exacerbation

First choice

Second choice

First choice

[amoxicillin](#)

[amoxicillin + clavulanic acid](#)

Second choice

[cefalexin](#)

[doxycycline](#)